Back to User profile » Dr Gabriella Fabbrocini
Papers published by Dr Gabriella Fabbrocini:
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, Aloisi E
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3561-3574
Published Date: 12 December 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2637-2644
Published Date: 25 September 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M
Psoriasis: Targets and Therapy 2023, 13:19-26
Published Date: 4 May 2023
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
Potestio L, Martora F, Fabbrocini G, Battista T, Megna M
Psoriasis: Targets and Therapy 2023, 13:11-18
Published Date: 12 April 2023
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study
Matteo M, Battista T, Noto M, Picone V, Fabbrocini G, Ruggiero A, Genco L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:553-564
Published Date: 2 March 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:529-536
Published Date: 27 February 2023
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:369-373
Published Date: 5 February 2023
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
Martora F, Megna M, Battista T, Potestio L, Annunziata MC, Marasca C, Villani A, Fabbrocini G
Clinical, Cosmetic and Investigational Dermatology 2023, 16:135-148
Published Date: 19 January 2023
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Ruggiero A, Martora F, Fabbrocini G, Villani A, Marasca C, Megna M, Fornaro L, Comune R, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2022, 15:2785-2793
Published Date: 19 December 2022
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2022, 15:2369-2382
Published Date: 6 November 2022
Towards Personalized Medicine in Psoriasis: Current Progress
Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:231-250
Published Date: 1 September 2022
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2022, 15:1649-1658
Published Date: 16 August 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Megna M, Potestio L, Fabbrocini G, Ruggiero A
Psoriasis: Targets and Therapy 2022, 12:205-212
Published Date: 14 July 2022
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:127-137
Published Date: 8 June 2022